EyePoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

+1.04 (+6.14%)
(As of 02:09 PM ET)
Today's Range
50-Day Range
52-Week Range
658,705 shs
Average Volume
994,637 shs
Market Capitalization
$896.44 million
P/E Ratio
Dividend Yield
Price Target

EyePoint Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
89.0% Upside
$34.00 Price Target
Short Interest
13.75% of Shares Sold Short
Dividend Strength
News Sentiment
0.91mentions of EyePoint Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$10.49 M Bought Last Quarter
Proj. Earnings Growth
From ($1.73) to ($2.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.19 out of 5 stars

Medical Sector

562nd out of 910 stocks

Analytical Instruments Industry

21st out of 26 stocks

EYPT stock logo

About EyePoint Pharmaceuticals Stock (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EYPT Stock Price History

EYPT Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call
EyePoint Pharmaceuticals: Q4 Earnings Snapshot
See More Headlines
Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$46.02 million
Book Value
$5.66 per share


Free Float
Market Cap
$844.62 million

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Jay S. Duker M.D. (Age 65)
    President, CEO & Director
    Comp: $848.5k
  • Dr. John B. Landis M.S. (Age 71)
    Ph.D., Interim Head of R&D and Director
    Comp: $63.75k
  • Mr. Michael Pine (Age 47)
    Chief Business Officer
    Comp: $764.85k
  • Mr. George O. Elston (Age 59)
    Executive VP & CFO
    Comp: $743.86k
  • Mr. Michael J. Maciocio
    Senior Vice President of Manufacturing & Operations
  • Mr. Ron I. Honig Esq.
    Chief Legal Officer & Company Secretary
  • Ms. Jennifer Leonard
    Chief People Officer & Senior VP of IT
  • Mr. David Scott Jones (Age 56)
    Senior VP & Chief Commercial Officer
    Comp: $672.08k
  • Ms. Isabelle Lefebvre
    Chief Regulatory Officer
  • Dr. Marcia Sellos-Moura Ph.D.
    Senior Vice President of Program Leadership

EYPT Stock Analysis - Frequently Asked Questions

Should I buy or sell EyePoint Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings
or view top-rated stocks.

What is EyePoint Pharmaceuticals' stock price target for 2024?

6 Wall Street research analysts have issued 12-month price objectives for EyePoint Pharmaceuticals' shares. Their EYPT share price targets range from $22.00 to $44.00. On average, they anticipate the company's stock price to reach $34.00 in the next year. This suggests a possible upside of 89.0% from the stock's current price.
View analysts price targets for EYPT
or view top-rated stocks among Wall Street analysts.

How have EYPT shares performed in 2024?

EyePoint Pharmaceuticals' stock was trading at $23.11 on January 1st, 2024. Since then, EYPT shares have decreased by 22.2% and is now trading at $17.99.
View the best growth stocks for 2024 here

When is EyePoint Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our EYPT earnings forecast

How were EyePoint Pharmaceuticals' earnings last quarter?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.27. The company had revenue of $14.03 million for the quarter, compared to the consensus estimate of $8.71 million. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative trailing twelve-month return on equity of 61.48%. During the same period in the previous year, the company posted ($0.61) earnings per share.

What ETFs hold EyePoint Pharmaceuticals' stock?

ETFs with the largest weight of EyePoint Pharmaceuticals (NASDAQ:EYPT) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Invesco Biotechnology & Genome ETF (PBE).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

When did EyePoint Pharmaceuticals' stock split?

EyePoint Pharmaceuticals shares reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of EyePoint Pharmaceuticals own?
Who are EyePoint Pharmaceuticals' major shareholders?

EyePoint Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Woodstock Corp (0.06%). Insiders that own company stock include Cormorant Asset Management, Lp, Dario A Paggiarino, David Scott Jones, Ew Healthcare Partners, LP, Michael Craig Pine and Ye Liu.
View institutional ownership trends

How do I buy shares of EyePoint Pharmaceuticals?

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EYPT) was last updated on 4/23/2024 by Staff

From Our Partners